Individual analysis of patients with HoFH participating in a phase 3 trial with lomitapide: The Italian cohort

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 26, Issue 1, 2016, Pages 36-44

  Averna, M ^a   Cefalu A B ^a   Stefanutti, C ^b   Di Giacomo, S ^b   Sirtori, C R ^c   Vigna, G ^d  

^a UNIVERSITY OF PALERMO   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF FERRARA   (Italy)

Author keywords

Familial hypercholesterolaemia; FH; HoFH; Homozygous familial hypercholesterolaemia; Lomitapide; Therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; EZETIMIBE; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOMITAPIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; BENZIMIDAZOLE DERIVATIVE; BIOLOGICAL MARKER; HYPOCHOLESTEROLEMIC AGENT; LDLR PROTEIN, HUMAN;

ABDOMINAL DISTENSION; ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLATULENCE; GASTROINTESTINAL DISEASE; GENE MUTATION; HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA; HUMAN; HYPERCHOLESTEROLEMIA; ITALIAN (CITIZEN); MALE; NAUSEA; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RECTAL TENESMUS; YOUNG ADULT; ADOLESCENT; BLOOD; CLINICAL TRIAL; GENETIC PREDISPOSITION; GENETICS; HETEROZYGOTE; HYPERLIPOPROTEINEMIA TYPE II; ITALY; MIDDLE AGED; MULTICENTER STUDY; MUTATION; PHENOTYPE; TIME FACTOR; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTICHOLESTEREMIC AGENTS; BENZIMIDAZOLES; BIOMARKERS; CHOLESTEROL, LDL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; ITALY; MALE; MIDDLE AGED; MUTATION; PHENOTYPE; RECEPTORS, LDL; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84952939391     PISSN: 09394753     EISSN: 15903729     Source Type: Journal    
DOI: 10.1016/j.numecd.2015.11.001     Document Type: Article

References (19)

1. Goldstein J.K., Hobbs H.H., Brown M.S. Familial hypercholesterolemia. The metabolic basis of inherited disease 2001, 2863-2913. McGraw-Hill, New York. 8th ed. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
2. Raal F.J., Santos R.D. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis 2012, 223:262-268.
3. Sjouke B., Kusters D.M., Kindt I., Besseling J., Defesche J.C., Sijbrands E.J., et al. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. Eur Heart J 2015, 36:560-565.
4. Cuchel M., Bruckert E., Ginsberg H.N., Raal F.J., Santos R.D., Hegele R.A., et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J 2014, 35:2146-2157.
5. Aegerion Pharmaceuticals Inc. Juxtapid prescribing information 2013.
6. Aegerion Pharmaceuticals Inc. Lojuxta summary of product characteristics 2015.
7. Cuchel M., Meagher E.A., du Toit Theron H., Blom D.J., Marais A.D., Hegele R.A., et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 2013, 381:40-46.
8. Cuchel M., Blom D.J., Averna M., Meagher E.A., du Toit Theron H., Sirtori C.R., et al. Sustained LDL-C lowering and stable hepatic fat levels in patients with homozygous familial hypercholesterolemia treated with the microsomal transfer protein inhibitor lomitapide: results of an ongoing long-term extension study. Paper presented at: American Heart Association Scientific Sessions 2013, Dallas, Texas, Abstract 16516.
9. Sirtori C.R., Catapano A.L., Franceschini G., Corsini A., Noseda G., Fragiacomo C., et al. Aortic and coronary atheromatosis in a woman with severe hypercholesterolaemia without LDL receptor alterations. Eur Heart J 1991, 12:818-824.
10. Nordestgaard B.G., Chapman M.J., Humphries S.E., Ginsberg H.N., Masana L., Descamps O.S., et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus Statement of the European Atherosclerosis Society. Eur Heart J 2013, 34:3478-3490a.
11. Leigh S. LDLR database 2011.
12. Letteron P., Sutton A., Mansouri A., Fromenty B., Pessayre D. Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice. Hepatology 2003, 38:133-140.
13. Stefanutti C., Vivenzio A., Di Giacomo S., Mazzarella B., Bosco G., Berni A. Aorta and coronary angiographic follow-up of children with severe hypercholesterolemia treated with low-density lipoprotein apheresis. Transfusion 2009, 49:1461-1470.
14. Bambauer R., Bambauer C., Lehmann B., Latza R., Schiel R. LDL-apheresis: technical and clinical aspects. Sci World J 2012, 2012:314283.
15. van Wijk D.F., Sjouke B., Figueroa A., Emami H., van der Valk F.M., MacNabb M.H., et al. Nonpharmacological lipoprotein apheresis reduces arterial inflammation in familial hypercholesterolemia. J Am Coll Cardiol 2014, 64:1418-1426.
16. Stefanutti C., Thompson G.R. Lipoprotein apheresis in the management of familial hypercholesterolaemia: historical perspective and recent advances. Curr Atheroscler Rep 2015, 17:465.
17. Bruckert E., Saheb S., Bonté J.R., Coudray-Omnès C. Daily life, experience and needs of persons suffering from homozygous familial hypercholesterolaemia: insights from a patient survey. Atheroscler Suppl 2014, 15:46-51.
18. Kroon A.A., van't Hof M.A., Demacker P.N., Stalenhoef A.F. The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels. Atherosclerosis 2000, 152:519-526.
19. Aegerion Pharmaceuticals Inc. Data on file.